Radium-223 chloride

Drug Profile

Radium-223 chloride

Alternative Names: AC1O4D1M; Alpharadin; ATI-BC-1; BAY88-8223; Radium Ra 233 dichloride; Radium-223; Radium-223 dichloride; Xofigo

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Algeta
  • Developer Algeta; Bayer HealthCare; Medica Scientia Innovation Research; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bone metastases
  • Phase I/II Multiple myeloma
  • Phase I Osteosarcoma
  • Discontinued Cancer pain

Most Recent Events

  • 30 May 2017 University of Freiburg, in collaboration with Bayer completes a phase II trial for Bone metastases (in castration-resistant prostate cancer) in Germany (NCT02484339)
  • 12 May 2017 Bayer completes a phase I/II retreatment trial for Bone metastases (from castrate-resistant prostate cancer) in USA, United Kingdom, Italy, Germany, Finland, Sweden, Norway, Ireland, Spain and Israel (IV) (NCT01934790)
  • 01 Apr 2017 Parmacodynamics data from preclinical studies in Multiple myeloma presented at the 108th Annual Meeting of the American Association for Cancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top